Mykronor (Noradrenaline Tartrate)

Norepinephrine stimulates α1‑adrenergic receptors on blood vessels, causing vasoconstriction and raising systemic vascular resistance. It also activates β1‑adrenergic receptors in the heart, enhancing contractility and heart rate. The combined effect increases arterial pressure and improves tissue perfusion during shock.

The dose of Mykronor is individualized. A qualified prescriber determines the starting infusion rate and titrates it based on the patient’s blood pressure response and clinical condition. Dosing is adjusted continuously in an intensive‑care environment.

Safety data for norepinephrine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Mykronor, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Mykronor (norepinephrine) is considered a first‑line vasopressor for most shock states because of its balanced α1‑mediated vasoconstriction and β1‑mediated cardiac support. Compared with agents such as phenylephrine (pure α1) or dopamine (dose‑dependent), norepinephrine typically offers more predictable blood‑pressure control with fewer tachyarrhythmic effects.

Mykronor must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique when preparing the IV infusion.

Mykronor is administered as an intravenous infusion. The solution is diluted in a compatible carrier fluid and delivered via a calibrated infusion pump. Continuous hemodynamic monitoring is essential, and the infusion rate is adjusted to achieve target blood‑pressure goals.

Serious risks include life‑threatening arrhythmias, severe hypertension, myocardial ischemia, and peripheral ischemic injury from excessive vasoconstriction. Prompt recognition of chest pain, abnormal heart rhythms, or sudden spikes in blood pressure is critical, and the infusion should be adjusted or stopped as clinically indicated.

Mykronor is contraindicated in patients with known hypersensitivity to norepinephrine or any of its excipients. Caution is advised in individuals with uncontrolled hypertension, severe peripheral vascular disease, or those receiving MAO inhibitors, as the drug may exacerbate these conditions.